WilmerHale represented the underwriters in the public offering of 9,200,000 shares of common stock of NeuBase Therapeutics, Inc., a biopharmaceutical company focused on developing a new class of precision genetic medicines, at a public offering price per share of $5.00. The shares of common stock sold reflected the full exercise of the underwriters’ option to purchase additional shares, and the gross proceeds to the company were $46 million, before deducting underwriting discounts and offering expenses. The offering priced on April 22, 2021 and closed on April 26, 2021.

The WilmerHale team advising the underwriters consisted of Glenn Pollner, Colleen Superko, Stephanie Leopold and Gerard Fischetti.